Signals, Powered By EquityPandit
Alembic Pharmaceuticals has received Establishment Inspection Report (EIR) from US FDA, after the inspection of its Panelav plant.
The inspection by USFDA was carried out at the formulation facility during the period from March 12 to March 20, 2018. Further, its API facility which is also located at Panelav, had received zero observations after the scheduled inspection in April. This scheduled inspection was conducted by USFDA, at API facility during April 16-23.
